Quadrant Capital Group LLC Exelixis, Inc. Transaction History
Quadrant Capital Group LLC
- $1.43 Billion
- Q4 2024
A detailed history of Quadrant Capital Group LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Quadrant Capital Group LLC holds 6,251 shares of EXEL stock, worth $235,350. This represents 0.01% of its overall portfolio holdings.
Number of Shares
6,251
Previous 6,011
3.99%
Holding current value
$235,350
Previous $155,000
34.19%
% of portfolio
0.01%
Previous 0.01%
Shares
29 transactions
Others Institutions Holding EXEL
# of Institutions
565Shares Held
251MCall Options Held
1.45MPut Options Held
1.13M-
Black Rock Inc. New York, NY33.5MShares$1.26 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.4MShares$1.11 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA23.4MShares$882 Million4.16% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.3MShares$576 Million0.8% of portfolio
-
State Street Corp Boston, MA11.4MShares$430 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $12.1B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...